{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:40:25Z","timestamp":1792291225329,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32-CA009515"],"award-info":[{"award-number":["T32-CA009515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1093\/annonc\/mdv022","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:30:37Z","timestamp":1421800237000},"page":"1291-1299","source":"Crossref","is-referenced-by-count":479,"title":["Genetics of breast cancer: a topic in evolution"],"prefix":"10.1016","volume":"26","author":[{"given":"S.","family":"Shiovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv022_bb0010","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0015","unstructured":"National Cancer Institute at the National Institutes of Health. Breast Cancer. http:\/\/www.cancer.gov\/cancertopics\/types\/breast (17 October 2013, date last accessed)."},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdv022_bb0020","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","article-title":"BRCA in breast cancer: ESMO Clinical Practice Guidelines","volume":"22","author":"Balmana","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0025","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) for Genetic\/Familial High-Risk Assessement: Breast and Ovarian V.4.2013. (c) National Comprehensive Cancer Network, Inc., 2013. All rights reserved. http:\/\/www.nccn.org (17 October 2013, date last accessed). NATIONAL COMPREHENSIVE CANCER NETWORK(r), NCCN(r), NCCN GUIDELINES(r), and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc."},{"key":"10.1093\/annonc\/mdv022_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.2007.53","article-title":"The emerging landscape of breast cancer susceptibility","volume":"40","author":"Stratton","year":"2008","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv022_bb0035","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv022_bb0040","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12\u201313","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv022_bb0045","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","article-title":"Basal-like breast cancer: a critical review","volume":"26","author":"Rakha","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0050","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0055","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv022_bb0060","first-page":"1","article-title":"Concise handbook of familial cancer susceptibility syndromes\u2014second edition","author":"Lindor","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1093\/annonc\/mdv022_bb0065","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","article-title":"Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature","volume":"22","author":"Liede","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0070","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"The Breast Cancer Linkage Consortium","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0075","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2159-8290.CD-12-0421","article-title":"Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer","volume":"3","author":"Domchek","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdv022_bb0085","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1038\/sj.onc.1209879","article-title":"Models of genetic susceptibility to breast cancer","volume":"25","author":"Antoniou","year":"2006","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv022_bb0090","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10549-012-2292-1","article-title":"Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast\/ovarian cancer patients","volume":"136","author":"Kwong","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00439-005-1297-9","article-title":"Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast\/ovarian cancer families","volume":"117","author":"Vezina","year":"2005","journal-title":"Hum Genet"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdv022_bb0100","doi-asserted-by":"crossref","first-page":"vi93","DOI":"10.1093\/annonc\/mdm234","article-title":"Founder mutations in BRCA1 and BRCA2 genes","volume":"18","author":"Ferla","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.2011.41.0027","article-title":"Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network","volume":"31","author":"Weitzel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0110","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.onc.1201984","article-title":"Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer","volume":"17","author":"FitzGerald","year":"1998","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv022_bb0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv022_bb0120","first-page":"6094","article-title":"Follow-up study of twenty-four families with Li-Fraumeni syndrome","volume":"51","author":"Garber","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv022_bb0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1054\/bjoc.2000.1530","article-title":"Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites","volume":"84","author":"Rapakko","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0130","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1038\/sj.onc.1204621","article-title":"Relative frequency and morphology of cancers in carriers of germline TP53 mutations","volume":"20","author":"Birch","year":"2001","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv022_bb0135","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1053\/gast.2001.29611","article-title":"Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families","volume":"121","author":"Pharoah","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdv022_bb0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-128-11-199806010-00004","article-title":"Increased risk for cancer in patients with the Peutz-Jeghers syndrome","volume":"128","author":"Boardman","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdv022_bb0145","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1053\/j.gastro.2004.03.014","article-title":"Relative frequency and morphology of cancers in STK11 mutation carriers","volume":"126","author":"Lim","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdv022_bb0150","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","article-title":"Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv022_bb0155","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/cncr.26424","article-title":"Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis","volume":"118","author":"Lowry","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0160","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv022_bb0165","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv022_bb0170","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0175","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1245\/s10434-011-1908-8","article-title":"Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?","volume":"18","author":"Reynolds","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","article-title":"Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers","volume":"46","author":"Evans","year":"2009","journal-title":"J Med Genet"},{"key":"10.1093\/annonc\/mdv022_bb0185","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1471-0528.2007.01499.x","article-title":"Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective","volume":"114","author":"Woodward","year":"2007","journal-title":"BJOG"},{"key":"10.1093\/annonc\/mdv022_bb0190","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0195","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/jnci\/djn327","article-title":"Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution","volume":"100","author":"Chlebowski","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0200","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer","volume":"91","author":"Gail","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0205","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0210","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv022_bb0215","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0220","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0225","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv022_bb0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Meijers-Heijboer","year":"2002","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv022_bb0235","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","article-title":"Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles","volume":"38","author":"Seal","year":"2006","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv022_bb0240","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv022_bb0245","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv022_bb0250","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","article-title":"Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population","volume":"14","author":"Shaag","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1093\/annonc\/mdv022_bb0255","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jnci\/dji141","article-title":"Cancer risks and mortality in heterozygous ATM mutation carriers","volume":"97","author":"Thompson","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0260","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/mutage\/get050","article-title":"Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?","volume":"28","author":"Gupta","year":"2013","journal-title":"Mutagenesis"},{"key":"10.1093\/annonc\/mdv022_bb0265","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/bcr3392","article-title":"Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families","volume":"15","author":"Teo","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv022_bb0270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-010-1001-1","article-title":"PALB2 analysis in BRCA2-like families","volume":"127","author":"Adank","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0275","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10549-012-1998-4","article-title":"Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing","volume":"133","author":"De Leeneer","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0280","doi-asserted-by":"crossref","first-page":"e52374","DOI":"10.1371\/journal.pone.0052374","article-title":"RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry Study","volume":"7","author":"Le Calvez-Kelm","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv022_bb0285","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-011-1700-2","article-title":"RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1\/2 hereditary breast cancer","volume":"133","author":"He","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0290","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-013-2692-x","article-title":"Clinical characteristics of breast cancer in patients with an NBS1 mutation","volume":"141","author":"Huzarski","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2407-9-181","article-title":"Variations in the NBN\/NBS1 gene and the risk of breast cancer in non-BRCA1\/2 French Canadian families with high risk of breast cancer","volume":"9","author":"Desjardins","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0300","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng.570","article-title":"Mutation of the RAD51C gene in a Fanconi anemia-like disorder","volume":"42","author":"Vaz","year":"2010","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv022_bb0305","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2350-14-82","article-title":"Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families","volume":"14","author":"Haanpaa","year":"2013","journal-title":"BMC Med Genet"},{"key":"10.1093\/annonc\/mdv022_bb0310","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0315","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/93.5.334","article-title":"Validating and improving models for projecting the absolute risk of breast cancer","volume":"93","author":"Gail","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0320","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","article-title":"Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction","volume":"73","author":"Claus","year":"1994","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0325","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/301670","article-title":"Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2","volume":"62","author":"Parmigiani","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mdv022_bb0330","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mdv022_bb0335","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","volume":"98","author":"Antoniou","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv022_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jacr.2012.09.036","article-title":"ACR appropriateness criteria breast cancer screening","volume":"10","author":"Mainiero","year":"2013","journal-title":"J Am Coll Radiol"},{"key":"10.1093\/annonc\/mdv022_bb0345","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdv022_bb0350","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv022_bb0355","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv022_bb0360","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gepi.20297","article-title":"Estimation of significance thresholds for genomewide association scans","volume":"32","author":"Dudbridge","year":"2008","journal-title":"Genet Epidemiol"},{"key":"10.1093\/annonc\/mdv022_bb0365","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-012-2364-2","article-title":"Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis","volume":"137","author":"Pabalan","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0370","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1470-2045(11)70076-6","article-title":"Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence","volume":"12","author":"Zhang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0375","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdv022_bb0380","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/0008-5472.CAN-08-0599","article-title":"The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families","volume":"68","author":"Palma","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv022_bb0385","unstructured":"University of Washington Department of Laboratory Medicine. BROCA\u2014Cancer Risk Panel. http:\/\/tests.labmed.washington.edu\/BROCA (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0390","unstructured":"University of Washington Department of Laboratory Medicine. ColoSeq\u2014Lynch and Polyposis Syndrome Panel. http:\/\/web.labmed.washington.edu\/tests\/genetics\/COLOSEQ (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0395","unstructured":"Ambry Genetics. Hereditary Cancer Panels. http:\/\/www.ambrygen.com\/hereditary-cancer-panels (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0400","unstructured":"GeneDx. Oncology Genetics. https:\/\/www.genedx.com\/oncology-genetics\/ (28 October2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0405","unstructured":"Baylor College of Medicine Medical Genetics Laboratories. Hereditary High Risk Breast Cancer Panel. https:\/\/www.bcm.edu\/research\/medical-genetics-labs\/test_detail.cfm?testcode=9155 (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0410","unstructured":"Baylor College of Medicine Medical Genetics Laboratories. Hereditary Breast\/Ovarian Cancer Panel. https:\/\/www.bcm.edu\/research\/medical-genetics-labs\/test_detail.cfm?testcode=9170 (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0415","unstructured":"Baylor College of Medicine Medical Genetics Laboratories. Comprehensive Hereditary Cancer Panel. https:\/\/www.bcm.edu\/research\/medical-genetics-labs\/test_detail.cfm?testcode=9130 (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0420","unstructured":"City of Hope Molecular Diagnostic Laboratory. Breast Cancer Susceptibility. http:\/\/www.cityofhope.org\/Breast_Cancer_Susceptibility_MDL (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0425","unstructured":"Sistemas Gen\u00f3micos. ONCO Gene Profile. https:\/\/www.sistemasgenomicos.com\/web_sg\/upload\/banner\/onco80-y-mammagene-ing.pdf (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0430","unstructured":"CeGaT GmbH\u2014Center for Genomics and Transcriptomics. Tumor Syndromes. http:\/\/www.cegat.de\/Tumor-syndromes_l=1_171.html (28 October 2013, date last accessed)."},{"key":"10.1093\/annonc\/mdv022_bb0435","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10549-012-2009-5","article-title":"Rare germline large rearrangements in the BRCA1\/2 genes and eight candidate genes in 472 patients with breast cancer predisposition","volume":"133","author":"Rouleau","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv022_bb0440","article-title":"More than 25% of breast cancer families with wild-type results from commercial genetic testing of BRCA1 and BRCA2 are resolved by BROCA sequencing of all known breast cancer genes","author":"Walsh","year":"2013","journal-title":"In American Society of Human Genetics"},{"key":"10.1093\/annonc\/mdv022_bb0445","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","article-title":"Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?","volume":"31","author":"Domchek","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv022_bb0450","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/humu.22214","article-title":"Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions","volume":"34","author":"Thompson","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1093\/annonc\/mdv022_bb0455","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10897-012-9506-x","article-title":"Personal genomic testing as part of the complete breast cancer risk assessment: a case report","volume":"21","author":"Riordan","year":"2012","journal-title":"J Genet Couns"},{"key":"10.1093\/annonc\/mdv022_bb0460","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1011893","article-title":"Effect of direct-to-consumer genomewide profiling to assess disease risk","volume":"364","author":"Bloss","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/7\/1291\/5198023\/mdv022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:53:38Z","timestamp":1624506818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419344813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0923753419344813"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv022","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}